Medicare Dialysis Drug Payments Should Be Based On ASP, MedPAC Says
Executive Summary
Medicare reimbursement for all injectable drugs used in dialysis facilities should be average sales price plus 6%, the Medicare Payment Advisory Commission's June report to Congress says
You may also be interested in...
Epogen Part B Payments To Be Based On ASP In All Dialysis Centers – CMS
Medicare will reimburse Amgen's Epogen (epoetin alfa) at the average sales price plus 6% in freestanding and hospital-based dialysis facilities in 2006 under the proposed FDL-1Physician Fee Schedule for 2006, announced Aug. 1
Epogen Part B Payments To Be Based On ASP In All Dialysis Centers – CMS
Medicare will reimburse Amgen's Epogen (epoetin alfa) at the average sales price plus 6% in freestanding and hospital-based dialysis facilities in 2006 under the proposed FDL-1Physician Fee Schedule for 2006, announced Aug. 1
EPO Reimbursement Report Suggests $10 Per Unit Is Close To Market Price
Actual market prices for Amgen's Epogen in the dialysis market range from $8.79 per unit to $9.50 per unit for most purchases, HHS' Office of the Inspector General said in a May 5 report